retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Frontiers | Type 2 diabetes

While SURPASS-4 was not powered to evaluate differences in MACE-4 incidence between tirzepatide treatment groups and glargine, it was designed to fulfill the MACE-4 non-inferiority analysis requested by regulatory authorities to evaluate the cardiovascular safety of new glucose lowering medications

They used a mouse model of diet-induced obesity and combined metabolomic analyses in BAT and other tissues with stable-isotope tracer studies to answer this question

Retatrutide is currently only accessible through clinical trials

- 3 mg (3000 mcg)**: The highest dose available, providing maximum benefits for appetite suppression and weight loss